No clinicopathologic features were significantly different between DLBCL patients with concurrent MYC/BCL6 rearrangements versus patients without MYC/BCL6 concurrent rearrangement, although larger tumor size was of borderline significance (P = 0.058). The gene discussed is BCL6; the disease is neoplasm.